Imitrex Sc

Sumatriptan, the active ingredient in Imitrex Sc, is a selective serotonin (5‑HT1B/1D) receptor agonist presented as a subcutaneous injection for acute migraine treatment in adults.

GNH USA supplies Imitrex Sc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality for acute migraine care. The company adheres to stringent quality standards, ensures proper cold‑chain handling for the injectable form, and offers flexible logistics to meet the needs of global healthcare providers.

Sumatriptan is used for the acute treatment of migraine, a neurovascular headache disorder.

- Migraine with aura: provides rapid relief of headache and associated symptoms. - Migraine without aura: reduces headache intensity and duration. - Acute episodic migraine: aborts an ongoing migraine attack and improves functional ability.

Common side effects are generally mild and transient.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Tingling or numbness: transient paresthesia in the face or extremities. - Warmth or flushing: sensation of heat spreading from the injection area. - Nausea: mild gastrointestinal upset. - Dizziness: brief feeling of light‑headedness. - Fatigue: temporary tiredness after administration.

Serious or Rare Side Effects: - Chest discomfort or tightness: may indicate cardiac ischemia. - Severe hypertension: sudden rise in blood pressure. - Serotonin syndrome: agitation, hyperreflexia, fever when combined with serotonergic agents. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Myocardial infarction or stroke: rare but life‑threatening vascular events. - Severe abdominal pain: could signal serious gastrointestinal complications.

Before using Imitrex Sc, consider the following precautions. - Cardiovascular disease: avoid use in patients with coronary artery disease, uncontrolled hypertension, or history of myocardial infarction. - Cerebrovascular disorders: contraindicated in patients with a history of stroke or transient ischemic attack. - Hemiplegic or basilar migraine: not recommended due to increased vascular risk. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Pregnancy and lactation: safety not established; use only if the potential benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sumatriptan may interact with several drug classes; monitor patients accordingly.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans: additive vasoconstrictive effects increase cardiovascular risk. - Ergot alkaloids: combined vasoconstriction may lead to serious ischemic events. - SSRIs, SNRIs, or other serotonergic agents: heightened risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): avoid concurrent use.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive blood pressure lowering. - CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma levels. - Oral contraceptives: monitor for increased migraine frequency. - Antihistamines: may enhance dizziness or fatigue. - Diuretics: watch for electrolyte disturbances that could affect vascular tone.